Fig. 2: Sensitivity analysis varying the cost of PAT. | Translational Psychiatry

Fig. 2: Sensitivity analysis varying the cost of PAT.

From: Psilocybin-assisted therapy for treatment-resistant depression in the US: a model-based cost-effectiveness analysis

Fig. 2

The vertical bars represent the expected incremental cost-effectiveness ratio of psilocybin-assisted therapy from limited healthcare and societal perspectives. The gray horizontal band represents the conventional cost-effectiveness threshold range used in the US ($100,000–150,000 per QALY gained). ICER incremental cost-effectiveness ratio, QALY quality-adjusted life year.

Back to article page